Learn why GLP-1 weight-management treatments produce widely varying results and see how treatment persistence and biology shape individual clinical outcomes.
On September 16, 2026, The Pharmaceutical Journal published new findings regarding the variable effectiveness of GLP-1 weight-management medicines. The detailed feature examines why individuals taking the same prescriptions can experience substantially different outcomes. Real-world patient results vary significantly, with some losing more than 25 percent of their body weight while others lose less than 5 percent.
This variation is highly relevant as an estimated 8 million UK adults have taken or are considering taking these treatments. The UK began a phased 12-year NHS rollout of these medicines in June 2025. The first three years of this rollout prioritize a cohort of 220,000 patients based on clinical need. Understanding how individual responses differ is now crucial for patients and clinicians navigating this expanding landscape.
GLP-1 medicines influence metabolic pathways and appetite regulation to support weight reduction. However, the underlying biology of each patient significantly shapes the final clinical result. Professor Katrina Bicknell suggests that body composition and sex hormones play a biological role in these variations. Because these medicines appear to reduce fat mass preferentially, men often see different outcomes since they naturally carry more muscle than women of the same size.
Bicknell also noted that reduced oestrogen after menopause might reduce the medication's effect, though this reduction was not observed in women taking hormone-replacement therapy. A patient's metabolic status also alters how these treatments function. Individuals with type 2 diabetes often experience different weight changes compared to those without the condition. This difference may be linked to insulin resistance, hyperinsulinaemia, and longer-standing metabolic disease.
Additionally, the use of weight-promoting diabetes medicines, such as insulin and sulfonylureas, can influence overall outcomes. Bicknell noted that reduced beta-cell function can limit how the treatment impacts insulin levels and insulin-dependent glucose metabolism, even when appetite is suppressed and gastric emptying is slowed. The specific medication mechanism and the administered dose are equally important biological factors. Different active compounds interact with the body in distinct ways.
A patient receiving the lowest approved dose of one medication will experience a different metabolic response than someone taking a higher dose of a newer combination therapy. Therefore, the intrinsic pharmacological effect of the medication must always be paired with the amount a person actually receives.
Mainstream media frequently portrays demographic differences in drug response as strict biological rules. Headlines often imply that sex, age, or ethnicity can reliably predict how much weight a person will lose. The reality presented in The Pharmaceutical Journal is that demographic categories often mask broader issues of treatment exposure and healthcare access. Current evidence does not justify using race or ethnicity alone to predict an individual outcome or to determine access.
At WeightRestart, we noticed that when these medications first began dominating the news, the media reaction was entirely polarized. Treatments were cast as either a perfect solution or a moral failure. We focused our editorial strategy on examining the clinical data and the actual limitations without any judgment. The immediate response from our audience confirmed how starved people were for objective facts over emotional sensationalism.
Much of the variation attributed to biology actually stems from treatment persistence. Patientric data highlighted that only 11.5 percent of patients in England’s most deprived fifth remained on GLP-1 treatment after one year. In contrast, 21.5 percent of patients in the least deprived fifth maintained their prescriptions. A separate Health Foundation analysis of 113,000 private prescriptions found that people in the most deprived areas accessed 32 percent fewer prescriptions overall.
Samantha Field of the Health Foundation pointed out that people facing the greatest burden of obesity appeared to be seeking private treatment less frequently, often beginning at higher BMIs. These persistence records do not capture the entire picture of medication adherence. Patientric could not track people who moved to another provider, meaning some apparent treatment discontinuations may represent provider switching rather than stopping medication altogether. Furthermore, patients with three or more health conditions demonstrated higher persistence than those without recorded health conditions, at 23.2 percent versus 16.5 percent.
This nuance proves that remaining on treatment is heavily influenced by systemic factors and clinical support rather than pure biological response alone.
Recent studies provide concrete numbers on how these treatments perform across different clinical groups. A June 2026 study of 20,678 people taking semaglutide or tirzepatide tracked those losing more than 15 percent of their body weight and those losing less than 5 percent. In the tirzepatide group achieving more than 15 percent weight loss, women represented 74.9 percent of the patients. A similar pattern emerged for semaglutide, where women accounted for 80.3 percent of high responders.
Despite these demographic concentrations, researchers emphasize that averages do not dictate individual results. In a 2025 meta-analysis of 14 randomised controlled trials, women lost an average of 1.04 kg more than men. Royal College of Pharmacy chief scientist Amira Guirguis described this difference as modest and emphasized substantial overlap between individuals. Population-level differences provide limited information about how a particular person will respond.
Clinical trials also demonstrate how metabolic conditions influence average outcomes. In the STEP 1 trial, adults without type 2 diabetes receiving semaglutide lost an average of 14.9 percent of their body weight after 68 weeks. Meanwhile, the STEP 2 trial showed that adults with type 2 diabetes receiving the same semaglutide dose lost an average of 9.6 percent over the same period. As we have previously discussed, these trial percentages do not tell the full treatment story, because glucose control and insulin sensitivity improvements hold equal clinical value.
The specific medication and dose also create measurable differences in average results. An updated systematic review reported placebo-subtracted weight loss of up to 5.8 percent for liraglutide, 14.8 percent for subcutaneous semaglutide, and 19.0 percent for tirzepatide. Conversely, a Reuters report on a study published in Biology Methods & Protocols examined recent data on low-dose GLP-1 treatments. At the lowest approved doses, average one-year weight loss was 5.5 percent with tirzepatide and 2.2 percent with semaglutide.
Age tracking reveals additional clinical patterns that require careful interpretation. The 2024 SELECT trial included more than 17,000 people and found progressively greater mean weight loss among younger participants, although the differences between age groups were small. A March 2026 analysis of 64 clinical trials found similar effectiveness in people younger than 65 and those aged 65 or older. The Health Foundation analysis noted that uptake was highest among people aged 30 to 49, falling sharply after age 60.
Finally, cessation data reveals the ongoing nature of obesity care. Clinical observations highlight that weight regain after stopping treatment is a common reality when medication is interrupted. This underscores that sustainable weight management requires ongoing support for nutrition, sleep, and physical function rather than expecting a temporary medication course to yield permanent results.
Future research must move beyond simple demographic categories to understand individual medication responses. The clinical evidence base is widening rapidly, with a September 2026 review reporting that 14 new obesity-drug trials were added over just 18 months. Scientists are beginning to evaluate genetic markers, such as variants in the PTPRU gene reported in a March 2026 study, to better explain differences in appetite regulation and energy use. However, true precision medicine will require tracking dose escalation, treatment persistence, and socioeconomic factors alongside genetic information.
Until these comprehensive models are developed, assessing a medication's value must include broader measures of physical function and metabolic health rather than focusing only on the scale. Older adults naturally face a decline in muscle mass, meaning further weight reduction could increase frailty risk in some people. For older or frail adults, treatment assessment should carefully prioritize muscle preservation, adequate nutrition, and physical function. Clinicians and patients must work together to tailor therapy goals, ensuring that long-term health remains the central focus of any pharmaceutical intervention.
WeightRestart shares research-led guidance on weight loss, metabolism, nutrition, strength, appetite, sleep and recovery. Our goal is to make complex health information clear, practical and useful for people building progress they can maintain.
Learn how to build a weight-management approach around better information, realistic expectations and habits you can keep using.
read the blog
